



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 12th day of August 2004.

PC27589A(1206)
Preliminary Amendment

s/


Bonnie Acosta



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Mark E. SCHNUTE et al.

Group Art Unit: 1625

Serial No.: 10/649,301

Examiner: Evelyn Huang

Confirmation No.: 5396

Filed: August 27, 2003

For: Heteroaryl-ethanolamine Derivatives
as Antiviral Agents

Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Amendment (⁸7 pages)
2. Change of Correspondence Address (one page)
3. Application Data Sheet (2 pages)
4. Postcard

Respectfully submitted,

Date: August 16, 2004


Karl O. Neidert
Attorney For Applicant
Registration No. 39,313

Agouron Pharmaceuticals, Inc.
A Pfizer Company
Legal Division, Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: 858/622-8060
Fax: 858/678-8233

IFW

Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of August 2004.

PC27589A(1206)
Preliminary Amendment



Bonnie Acosta

Bonnie Acosta

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Mark E. SCHNUTE et al.

Group Art Unit: 1625

Serial No.: 10/649,301

Examiner: Evelyn Huang

Confirmation No.: 5396

Filed: August 27, 2003

**For: Heteroaryl-ethanolamine Derivatives
as Antiviral Agents**

Mail Stop: Amendment
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

Responsive to the Office Action mailed May 27, 2004, please amend the above-identified application as follows:

- ☐ **Amendments to the Specification** begin on page _ of this paper.
- ☒ **Amendments to the Claims** are reflected in the listing of claims, which begins on page 3 of this paper.
- ☐ **Amendments to the Drawings** begin on page ___ of this paper and include both an attached replacement sheet and an annotated sheet showing changes.
- ☒ **Remarks** begin on page 5 of this paper.

Amendments to the Specification: There are no amendments to the specification.